Want to see HK:0455 full AI Analyst Report?
Top Page
Tianda Pharmaceuticals Ltd.
(0455)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.08
▼(-36.92% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by weak financial performance (persistent and worsening losses, margin pressure, and declining revenue) and a bearish technical setup (price below key moving averages with negative MACD). Improved 2025 operating/free cash flow and oversold momentum readings provide some support, but are not yet strong enough to outweigh profitability and trend risks.
Positive Factors
Manageable leverage / balance sheet
Sustained low-to-moderate debt ratios provide structural financial flexibility. With debt-to-equity near 0.19–0.29, interest burdens and refinancing pressure are limited, allowing the company to fund operations or R&D without immediate solvency stress, supporting multi-month resilience.
Negative Factors
Persistent and worsening net losses
Deepening negative net margins indicate structural profitability weaknesses. A widening loss profile erodes retained earnings and limits reinvestment capacity, increasing the likelihood of equity dilution or strategic cutbacks if sustained across quarters, impairing long-term value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage / balance sheet
Sustained low-to-moderate debt ratios provide structural financial flexibility. With debt-to-equity near 0.19–0.29, interest burdens and refinancing pressure are limited, allowing the company to fund operations or R&D without immediate solvency stress, supporting multi-month resilience.
Read all positive factors
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$184.90M
Dividend YieldN/A
Average Volume (3M)84.94K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-2.12%
EPS Growth-13.99%
CountryHK
Employees701
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September ...
How the Company Makes Money
null...
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 322.94M | 329.94M | 532.09M | 546.69M | 509.96M |
| Gross Profit | 133.31M | 152.02M | 255.53M | 251.52M | 241.22M |
| EBITDA | -24.41M | -49.49M | 15.66M | -19.89M | -5.14M |
| Net Income | -70.00M | -61.37M | -24.16M | -54.64M | -21.67M |
Balance Sheet | |||||
| Total Assets | 747.83M | 765.02M | 917.29M | 1.09B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 64.81M | 85.69M | 162.44M | 343.44M | 334.00M |
| Total Debt | 132.66M | 127.44M | 113.60M | 141.05M | 160.43M |
| Total Liabilities | 291.46M | 259.36M | 325.35M | 434.23M | 375.08M |
| Stockholders Equity | 456.64M | 505.84M | 592.07M | 627.83M | 756.75M |
Cash Flow | |||||
| Free Cash Flow | 2.80M | -52.30M | -116.04M | 54.73M | -61.98M |
| Operating Cash Flow | 14.42M | -9.70M | -49.76M | 79.11M | -8.23M |
| Investing Cash Flow | -20.38M | -31.77M | -69.10M | -12.20M | 86.35M |
| Financing Cash Flow | -15.31M | -30.65M | -57.39M | -28.98M | -1.29M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Neutral
0.13
Price Trends
0.09
Negative
0.10
Negative
0.12
Negative
Market Momentum
>-0.01
Positive
48.19
Neutral
8.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Neutral. The current price of 0.13 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and above the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.19 is Neutral, neither overbought nor oversold. The STOCH value of 8.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$741.70M | 7.93 | 12.80% | 7.52% | -9.66% | 16.17% | |
72 Outperform | HK$1.54B | 6.30 | 6.40% | 5.16% | 16.09% | -62.16% | |
54 Neutral | HK$185.60M | -0.48 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$317.60M | 77.78 | -1.17% | 7.50% | -8.30% | -44.44% | |
45 Neutral | HK$157.81M | -3.45 | -30.35% | ― | -12.03% | 6.24% | |
44 Neutral | HK$184.90M | -2.61 | -11.18% | ― | -2.12% | -13.99% |
* Healthcare Sector Average
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.05
-36.30%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.06
-0.02
-23.81%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.29
-0.02
-5.00%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.21
-41.00%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.02
-0.15
-12.89%
HK:0239
Pak Fah Yeow International Limited
2.38
0.03
1.28%
Tianda Pharmaceuticals Ltd. Corporate Events
Tianda Pharmaceuticals Wins Strong Shareholder Backing at 2026 AGM
Jun 12, 2026
Tianda Pharmaceuticals shareholders overwhelmingly approved all ordinary resolutions at the annual general meeting held on 12 June 2026, including adoption of the 2025 audited financial statements and re-election of key board members. The meeting ...
Tianda Pharmaceuticals Sets 2026 AGM and Seeks Share Buyback Mandate
Apr 29, 2026
Tianda Pharmaceuticals Limited has called its annual general meeting for 12 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and reports for the year ended 31 December 2025. The agenda also inclu...
Tianda Pharmaceuticals Sets Key Dates for 2026 AGM and Share Register Closure
Apr 29, 2026
Tianda Pharmaceuticals Limited has scheduled its 2026 annual general meeting for 12 June 2026 in Central, Hong Kong, setting 9 June 2026 as the record date for shareholders entitled to attend, speak and vote. To facilitate this, the company will c...
Tianda Pharmaceuticals Posts Wider 2025 Loss on Goodwill Impairment Despite Lower Expenses
Mar 26, 2026
Tianda Pharmaceuticals reported 2025 revenue of HK$322.9 million, slightly down from HK$329.9 million a year earlier, as the group maintained gross profit of HK$133.3 million but faced higher cost of sales. The company continues to operate across ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.